Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data s Profits Fall by 59 Percent in Q3; Revenues Essentially Unchanged

NEW YORK, Nov. 15 (GenomeWeb News) - Clinical Data today announced a slight decrease in revenues and a 59-percent decrease in net income for the third quarter.


For the quarter ended Sept. 30, Clinical Data reported revenues of $12.9 million, down a hair from $13 million the same quarter a year ago. Clinical Data's net income decreased to $377,000, or $0.09 per basic share, in Q3, from $910,000, or $0.21 per basic share, in the year-ago period.


The company did not break out R&D expenses or cash on hand.


In October, Clinical Data closed on a $56 million acquisition of Genaissance.


"Our efforts at integrating the operations of Genaissance Pharmaceuticals are progressing well as we refocus Genaissance's service offerings and streamline its operations," Israel Stein, Clinical Data's president, said in a statement.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.